Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Standard BioTools Inc. reports developments in life-science research tools built around proprietary mass cytometry and microfluidics technologies. The company sells instruments, consumables and services for genomics, single-cell proteomics and spatial proteomics, including platforms such as Biomark X9, CyTOF XT and Hyperion systems used in research workflows.
Recurring news includes operating and financial results, capital-structure updates, shareholder voting and governance matters, portfolio actions following the completed sale of SomaLogic assets, and collaborations that expand imaging mass cytometry and multi-omic research applications. Company updates also describe translational and clinical research use cases in oncology, immunology and immunotherapy, with products positioned for research use rather than diagnostic procedures.
Standard BioTools (NASDAQ: LAB) has unveiled new proteomic product innovations at AACR 2025, including the SomaScan Select 3.7K Assay, Single SOMAmer Reagents, and the next-generation CyTOF XT PRO system.
The SomaScan Select 3.7K Assay offers 3,700 unique human protein measurements and covers 70% of FDA standard clinical biomarkers. Single SOMAmer Reagents provide access to approximately 11,000 unique DNA-based reagents for protein measurement. The CyTOF XT PRO System enables simultaneous analysis of 50-plus biomarkers with up to 4x faster throughput.
The company will host a panel discussion on April 28 titled 'Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts.' Additionally, 90 scientific posters and presentations powered by Standard BioTools' proteomic portfolio will be presented at AACR 2025.
Standard BioTools (NASDAQ: LAB) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will disclose its Q1 2025 results on Tuesday, May 6, 2025, after the market closes.
A conference call and webcast are scheduled for the same day at 4:30 p.m. ET. Investors can participate through the following dial-in numbers:
- US domestic: (888) 346-3970
- International: (412) 902-4297
The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com for future reference.
Standard BioTools (NASDAQ: LAB) has announced its participation in three major investor conferences in March 2025. The company will present at TD Cowen's 45th Annual Healthcare Conference on March 3rd at 3:10 p.m. ET, attend investor meetings at the 2025 Leerink Partners Global Healthcare Conference on March 12th, and present at KeyBanc's 5th Annual Healthcare Forum on March 19th at 4:30 p.m. ET.
All presentations will be available via webcast on the company's Investor Relations website, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) reported its Q4 and full year 2024 financial results, with full-year pro forma combined revenue of $175.1 million. The company achieved significant operational improvements, including a 17% reduction in pro forma operating loss and 33% year-over-year improvement in adjusted EBITDA.
Key financial highlights include additional $10 million in operational cost reductions, totaling $90 million in synergies over 12 months, and a strong balance sheet with $295 million in cash and no material debt. The company expects to reach adjusted EBITDA positive in 2026.
Q4 2024 revenue was $46.7 million, down 9% year-over-year, with consumables revenue up 10%, instruments revenue down 25%, and services revenue down 16%. For fiscal year 2025, Standard BioTools projects revenue between $165-175 million, factoring in anticipated NIH funding pressures in Americas academic revenue.
Standard BioTools (NASDAQ: LAB) has announced its upcoming fourth quarter and full year 2024 earnings conference call, scheduled for February 26, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.
Investors can join via phone using (888) 346-3970 for US domestic callers or (412) 902-4297 for international participants. A live webcast will be available on the company's Investor Relations page, with an archived version accessible afterward at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) announced preliminary, unaudited revenue results for Q4 and the full year 2024.
For Q4, the company expects revenue of approximately $46.5 million, contributing to a full-year revenue of around $174 million. This meets the top end of their revised guidance, adjusted in Q2 to account for industry-wide challenges.
CEO Michael Egholm highlighted significant progress in reducing operating expenses through the implementation of Standard BioTools Business Systems (SBS). He emphasized the need for continued discipline and improvement. Looking ahead to 2025, the company aims to achieve further efficiencies from integration, enhancing their R&D and shifting revenues towards high-margin offerings.
Egholm expressed optimism about the company's strategy and team, aiming for long-term value for shareholders and customers. The company will report detailed financial results for Q4 and the full year 2024 later this quarter, along with their 2025 outlook.
The preliminary results are subject to completion of annual audit procedures and internal reviews.
Standard BioTools (NASDAQ: LAB) announced that its SomaScan Platform was instrumental in a Nature Medicine study examining semaglutide's effects on obesity treatment. The research, conducted by Novo Nordisk, analyzed approximately 6,400 human proteins across nearly 2,000 participants from two phase 3 trials.
The study revealed significant changes in protein biomarkers linked to metabolic pathways, providing new insights into semaglutide's biological mechanisms and potential broader health benefits. The SomaScan Technology demonstrated unique advantages, including mechanistic insights into proteins and pathways, reliable results across studies, and the potential to accelerate clinical development through a validated 27-protein predictor that detected cardiovascular benefits in smaller, shorter studies.